Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 13, 2024 12:40 PM 3 min read

'Give Me A Break, New York Times,' Says Actor Jim Belushi As He Defends Cannabis, Criticizes Big Pharma, Food Industry

by Javier Hasse

Actor and cannabis advocate Jim Belushi took the stage at the recent Benzinga Cannabis Capital Conference in Chicago to share his passionate views on the food and pharmaceutical industries, cannabis' healing potential and his frustration with media narratives around the plant.

Belushi, well-known for his cannabis farm in Oregon, did not mince words as he linked the food and pharmaceutical industries, alleging a symbiotic relationship that profits from public health crises. "I think food companies and Big Pharma are like hand in hand," he said. "Let's make processed foods. Everybody's gonna have diabetes and heart attacks, so Big Pharma can sell a lot of opiates and prescription drugs."

While these statements reflect his opinion, critics argue that such sweeping generalizations require more nuanced evidence. Nevertheless, Belushi's comments tap into a broader critique often shared by wellness advocates, who argue that the prevalence of processed foods and pharmaceutical dependencies negatively impact public health.

Frustration With Media Narratives

Belushi turned his attention to the media, singling out The New York Times for its reporting on Cannabinoid Hyperemesis Syndrome (CHS), a condition linked to chronic cannabis use that causes severe nausea and vomiting. "I read the New York Times…they wrote a whole article about this … challenge that cannabis has of people throwing up," he said. "Tequila makes me throw up. So does vodka … and so does bad chicken. People throw up. They want to go like, ‘Oh, this is what's bad about cannabis.' Give me a break."

Medical experts acknowledge that CHS is a documented condition, but its prevalence remains limited compared to other public health issues. Belushi's remarks highlight his belief that the media disproportionately scrutinizes cannabis while downplaying the harms associated with legal substances like nicotine and alcohol. "The government already knows that nicotine kills people. That alcohol contributes to so many deaths. Yet it's fine," he argued.

A Call For Fair Treatment

Belushi's core message centered on the perceived inequities in how cannabis is regulated and taxed compared to other substances. He pointed out the punitive history of cannabis enforcement and contrasted it with the leniency granted to industries like tobacco and alcohol. "Nobody gets thrown in jail in those businesses," he said. "So why are they picking on us? Leave us alone. We're peaceful people. We're trying to heal people. We're trying to have a nice time and feel good."

Belushi's impassioned statements resonated with an audience of cannabis industry professionals, many of whom share similar frustrations with outdated stigma and regulatory barriers.

Balancing Advocacy With Facts

While Belushi's advocacy shines a light on important issues, some of his claims warrant closer scrutiny. For instance, while CHS is indeed real, dismissing it outright could overlook the importance of raising awareness about potential risks associated with cannabis use. Additionally, his critique of the food and pharmaceutical industries, though rooted in widely shared sentiments, lacks specific examples or data to substantiate the alleged collaboration.

Belushi's appearance at the Benzinga Cannabis Capital Conference underscores the tension between cannabis advocates and traditional power structures, from Big Pharma to mainstream media. His call for equitable treatment reflects broader industry challenges as cannabis professionals work to overcome stigma, regulatory hurdles and public skepticism.

Photo courtesy of Belushi’s Farm.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
CannabisExclusivesInterviewJim BelushiNY Times
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...